电邮这篇文章 
PDE5 inhibitors in treatment of erectile dysfunction and cardiovascular safety
- 作者: Korneyev I.A.1
-
隶属关系:
- First State Pavlov Medical University of St Petersburg
- 期: 卷 5, 编号 2 (2015)
- 页面: 28-30
- 栏目: Articles
- URL: https://journals.eco-vector.com/uroved/article/view/2895
- DOI: https://doi.org/10.17816/uroved5228-30
- ID: 2895
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
Erectile dysfunction (ED) is a disease marker for cardiovascular disease. Men with ED should be properly assessed and investigated before starting treatment. The PDE5 inhibitors, including sildenafil, proved to be safe and effective treatment for this disorder.
全文:
作者简介
Igor Korneyev
First State Pavlov Medical University of St Petersburg
Email: iakorneyev@yandex.ru
doctor of medical science, professor. Department of Urology
参考
- Dong J. Y., Zhang Y. H., Qin L. Q. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies // J Am Coll Cardiol. 2011. Vol. 58, N 13. P. 1378-1385.
- Gazzaruso C., Coppola A., Montalcini T. et al. Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes // Endocrine. 2011. Vol. 40, N 2. P. 273-279.
- Nehra A., Jackson G., Miner M. et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease // Mayo Clin Proc. 2012. Vol. 87, N 8. P.766-778.
- Cheitlin M. D. Sexual activity and cardiac risk // Am J Cardiol. 2005. Vol. 96. 24M-28M.
- Kostis J., Jackson G., Rosen R. et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference) // Am J Cardiol. 2005. Vol. 96, N 2. P. 313-321.
- Guay A. T. Optimizing response to phosphodiesterase therapy: impact of risk-factor management // J Androl. 2003. Vol. 24, N 6 (Suppl). S59-S62.
- Moyad M. A., Barada J. H., Lue T. F. et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I // Urol Clin North Am. 2004. Vol. 31, N 2. P.249-257.
- Moyad M. A., Barada J. H., Lue T. F. et al. Sexual Medicine Society Nutraceutical Committee. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II // Urol Clin North Am. 2004. Vol. 31, N 2. P.259-273.
- Greenstein A., Mabjeesh N. J., Sofer M. et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? // J Urol. 2005. Vol.173, N 2. P. 530-532.
- Cheitlin M. D., Hutter A. M. Jr, Brindis R. G. et al. Technology and Practice Executive Committee. Use of sildenafil (Viagra) in patients with cardiovascular disease [published correction appears in Circulation. 1999;100:2389] // Circulation. 1999. Vol. 99. P.168 -177.
- Padma-Nathan H., Eardley I., Kloner R. A. et al. A 4-year update on the safety of sidlenafil citrate (Viagra) // Urology. 2002. Vol. 60 (Suppl 2B). P. 67-90.
- Herrmann H. C., Chang G., Klugherz B. D. et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease // N Engl J Med. 2000. Vol. 342, № 22. P.1622-1626.
- Carson C. C. III. Sildenafil: A 4-Year Update in the Treatment of 20 Million Erectile Dysfunction Patients // Current Urology Reports. 2003. Vol. 4. P. 488-496.
- Корнеев И. А. Длительное ингибирование фосфодиэстеразы 5 типа: эффекты, перспективы применения в урологической практике // Эффективная фармакотерапия. 16/2013. Урология и нефрология. № 2. С. 14-17.
- Мазо Е. Б., Гамидов С. И., Овчинников Р. И., Иремашвили В. В. Безопасность сексуальной активности у больных сердечно-сосудистыми заболеваниями // Фарматека. 2004. N 11. С. 8-12.
补充文件
